标题/作者	年份
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ... Journal of clinical oncology 39 (36), 4073-4126	2021
Immune checkpoint inhibitor–related dermatologic adverse events AN Geisler, GS Phillips, DM Barrios, J Wu, DYM Leung, AP Moy, JA Kern, ... Journal of the American Academy of Dermatology 83 (5), 1255-1268	2020
The growing incidence of bullous pemphigoid: overview and potential explanations K Kridin, RJ Ludwig Frontiers in medicine 5, 220	2018
Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls EP Darnell, MJ Mooradian, EN Baruch, M Yilmaz, KL Reynolds Current oncology reports 22, 1-11	2020
Bullous pemphigoid D Miyamoto, CG Santi, V Aoki, CW Maruta Anais brasileiros de dermatologia 94, 133-146	2019
Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy J Siegel, M Totonchy, W Damsky, J Berk-Krauss, F Castiglione Jr, M Sznol, ... Journal of the American Academy of Dermatology 79 (6), 1081-1088	2018
The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease KT Amber, M Valdebran, K Kridin, SA Grando Frontiers in Medicine 5, 201	2018
Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management A Muntyanu, E Netchiporouk, W Gerstein, R Gniadecki, IV Litvinov Journal of Cutaneous Medicine and Surgery 25 (1), 59-76	2021
A systematic review of drug-induced pemphigoid MJ Verheyden, A Bilgic, DF Murrell Acta dermato-venereologica 100 (15), 1-9	2020
Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus KT Amber, M Valdebran, SA Grando Autoimmunity Reviews 17 (10), 1002-1010	2018
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors OH Ali, D Bomze, SS Ring, F Berner, M Fässler, S Diem, MT Abdou, ... Journal of the American Academy of Dermatology 82 (4), 854-861	2020
Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1/programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature C Zumelzu, M Alexandre, C Le Roux, P Weber, A Guyot, A Levy, ... Frontiers in medicine 5, 268	2018
Systemic therapies for advanced melanoma L Bomar, A Senithilnathan, C Ahn Dermatologic Clinics 37 (4), 409-423	2019
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis S Wongvibulsin, V Pahalyants, M Kalinich, W Murphy, KH Yu, F Wang, ... Journal of the American Academy of Dermatology 86 (3), 563-572	2022
Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature A Tsiogka, JW Bauer, A Patsatsi Acta dermato-venereologica 101 (1), adv00377-adv00377	2021
Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors DJ Lee, HJ Lee, JR Farmer, KL Reynolds Current Cardiology Reports 23, 1-12	2021
The role of collagen XVII in cancer: squamous cell carcinoma and beyond VA Jones, PM Patel, FT Gibson, A Cordova, KT Amber Frontiers in Oncology 10, 352	2020
European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement Z Apalla, V Nikolaou, D Fattore, G Fabbrocini, A Freites‐Martinez, ... Journal of the European Academy of Dermatology and Venereology 36 (3), 332-350	2022
Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials W Yang, S Li, Q Yang Medicine 98 (20)	2019
Cutaneous adverse events of immune checkpoint inhibitors: a literature review Z Apalla, C Papageorgiou, A Lallas, F Delli, C Fotiadou, C Kemanetzi, ... Dermatology practical & conceptual 11 (1)	2021

1 - 20

计算机程序会自动估算并确定日期和引用次数。